Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture

Each participant of the study will have their data collected from the date of confirmed diagnosis of DC to the date of enrollment in the registry, post consent. Data will be collected from the participants clinical records as well as from the participant directly. Data will be collected through Pulse Infoframe's technology platform.

Primary outcomes

• Number of Participants Receiving Each Treatment Type for DC [Up to 36 months]

Secondary outcomes

• Change from Baseline in Michigan Hand Questionnaire (MHQ) Scale Score [Up to 36 months]
• Change from Baseline in European Quality of Life Five Dimension (EQ-5D) Questionnaire Score [Up to 36 months]
• Change from Baseline in Unité Rhumatologique des Affections de la Main (URAM) Scale Score [Up to 36 months]
• Participant Satisfaction Questionnaire [Up to 36 months]
• Number of Participants Receiving Post-Procedural Care by the Treating Physician [Up to 36 months]

Sex: All, ages: 18 Years to any

Key Inclusion Criteria:

* Any adult with a confirmed clinical diagnosis of DC.
* Age 18 years (or age of majority in their jurisdiction) or older at time of enrollment.
* Willing to participate in the registry (including completion of ePROs) and complete the informed consent form.
* Having received DC treatment, either non-surgical or surgical, within 2 weeks before enrollment, at enrollment or any time after the date of enrollment or not having received DC treatment after confirmed diagnosis of DC.
* Able to participate in English based registry.

Key Exclusion criteria:

* Not having a clinical diagnosis of DC.
* Age less than 18 years.
* Do not provide informed consent.

• Medical Information, Study director, Endo USA Inc., a Keenova Therapeutics Company